{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:05:16Z","timestamp":1760425516747,"version":"3.41.0"},"reference-count":32,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":397,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJPsych Bull"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Aims and method<\/jats:title><jats:p>We examined non-medical use (NMU) of olanzapine among adults on methadone treatment. Information was collected on patient demographics and NMU of olanzapine. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was administered to assess risk among current users of olanzapine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety-two clients participated and 30% reported lifetime history of NMU of olanzapine. Nine people reported doses of 30 mg or higher on a typical day of use, with three typically using 100 mg. The most common reasons for use were to relieve anxiety and to aid sleep, but a quarter used it to \u2018get stoned\u2019. Eleven participants (12%) reported NMU of olanzapine in the preceding month. Eight completed the ASSIST with four scoring in the high-risk zone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical implications<\/jats:title><jats:p>Self-medication is the dominant motivator for NMU of olanzapine, but hedonic motivations also occur. A small minority show features of dependency. All doctors should be aware of the potential NMU of olanzapine, especially among patients with history of addiction.<\/jats:p><\/jats:sec>","DOI":"10.1192\/pb.bp.115.052886","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T08:31:54Z","timestamp":1480581114000},"page":"314-317","source":"Crossref","is-referenced-by-count":7,"title":["Non-medical use of olanzapine by people on methadone treatment"],"prefix":"10.1192","volume":"40","author":[{"given":"Philip David","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Shaik","family":"Fida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Konovalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobby P.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S2056469400002515_ref3","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2013.825029"},{"key":"S2056469400002515_ref13","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2007.10400617"},{"key":"S2056469400002515_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3180f62d53"},{"key":"S2056469400002515_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1986.tb00299.x"},{"key":"S2056469400002515_ref16","article-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility","volume":"97","year":"2002","journal-title":"Addiction"},{"key":"S2056469400002515_ref25","doi-asserted-by":"publisher","DOI":"10.1177\/070674370304800208"},{"volume-title":"2012 Figures from the National Drug-Related Deaths Index","year":"2014","key":"S2056469400002515_ref30"},{"key":"S2056469400002515_ref27","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9781615378074","volume-title":"The Evidence-Based Guide to Antipsychotic Medications","author":"Rothschild","year":"2010"},{"key":"S2056469400002515_ref28","article-title":"Bloodbourne viral infection in Irish injecting drug users","volume":"92","author":"Smyth","year":"1998","journal-title":"Addiction"},{"key":"S2056469400002515_ref15","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2012.709222"},{"key":"S2056469400002515_ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04001.x"},{"key":"S2056469400002515_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(94)01088-3"},{"key":"S2056469400002515_ref20","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070112"},{"key":"S2056469400002515_ref10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.9.1755-a"},{"key":"S2056469400002515_ref7","article-title":"Abuse and misuse of antidepressants","volume":"5","author":"Evans","year":"2014","journal-title":"Subst Abuse Rehabil"},{"key":"S2056469400002515_ref1","doi-asserted-by":"publisher","DOI":"10.3109\/09687637.2011.594114"},{"key":"S2056469400002515_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033464"},{"key":"S2056469400002515_ref6","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v02n0502"},{"key":"S2056469400002515_ref2","doi-asserted-by":"crossref","DOI":"10.1071\/HC12106","article-title":"Prescription drug misuse: quantifying the experiences of New Zealand GPs","volume":"4","author":"Sheridan","year":"2012","journal-title":"J Prim Health Care"},{"key":"S2056469400002515_ref8","first-page":"59","article-title":"Abuse of neuroleptic drugs by psychiatric patients","volume":"54","author":"Basu","year":"2000","journal-title":"Indian J Med Sci"},{"key":"S2056469400002515_ref24","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00016"},{"key":"S2056469400002515_ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.9.1718"},{"key":"S2056469400002515_ref11","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060226"},{"key":"S2056469400002515_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(01)00205-7"},{"key":"S2056469400002515_ref21","article-title":"Aripiprazole, alcohol and substance abuse: a review","volume":"16","author":"Brunetti","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"S2056469400002515_ref26","doi-asserted-by":"publisher","DOI":"10.1080\/10550490500419052"},{"key":"S2056469400002515_ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.05024.x"},{"key":"S2056469400002515_ref19","article-title":"Potential benefits of quetiapine in the treatment of substance dependence disorders","volume":"29","author":"Sattar","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"S2056469400002515_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.07.031"},{"key":"S2056469400002515_ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00491.x"},{"key":"S2056469400002515_ref22","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700710"},{"key":"S2056469400002515_ref29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-10-42"}],"container-title":["BJPsych Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056469400002515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:45:04Z","timestamp":1749771904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056469400002515\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2056469400002515"],"URL":"https:\/\/doi.org\/10.1192\/pb.bp.115.052886","relation":{},"ISSN":["2056-4694","2056-4708"],"issn-type":[{"type":"print","value":"2056-4694"},{"type":"electronic","value":"2056-4708"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}